Supporting ADHD Awareness: The Role of RELEXXII
This month marks a significant time for acknowledging and educating people about Attention Deficit Hyperactivity Disorder (ADHD). Alora Pharmaceuticals, the leading manufacturer behind RELEXXII® (methylphenidate hydrochloride extended-release tablet), is deeply committed to this cause. ADHD impacts various dimensions of life, including educational achievement, workplace performance, and personal relationships. In this context, raising awareness is vital to offer better support and understanding to those affected by ADHD.
Understanding ADHD: A Lifelong Challenge
ADHD is one of the most common neurodevelopmental disorders diagnosed in children. However, it is crucial to recognize that ADHD can persist throughout a person's life. Symptoms of this condition typically appear in childhood but can extend into adulthood. Timely recognition of ADHD symptoms is an essential first step toward an accurate diagnosis, paving the way for effective treatment strategies.
Statistics on ADHD Prevalence
According to current research, around 10.2% of children aged 3 to 17 in the U.S. have been diagnosed with ADHD. When it comes to adults, the estimates suggest that approximately 4-5% live with the disorder. These figures illustrate a substantial population affected by ADHD, emphasizing the importance of awareness and support initiatives.
Treatment Approaches: Medication and Behavioral Therapy
ADHD treatment often combines medication with behavioral therapy for the best outcomes. Medications like RELEXXII® are stimulant-based and are recognized as among the most effective options for managing ADHD symptoms. Research indicates that stimulant medications can lead to a reduction of symptoms in 70-80% of children diagnosed with ADHD. These results highlight the importance of medication in achieving better management of the disorder.
The Importance of Awareness and Understanding
Building awareness about ADHD can significantly impact individuals living with the disorder. Shannon Faught, the Chief Commercial Officer of Alora Pharmaceuticals, notes that improving awareness is crucial for dismantling barriers and fostering comprehensive understanding. Effective diagnosis and management of ADHD can profoundly enhance the quality of life for patients and their families.
About Alora Pharmaceuticals: A Commitment to Quality
Alora Pharmaceuticals, LLC, the parent company of several specialized pharmaceutical organizations, is headquartered in Alpharetta, Georgia. Their dedication lies not only in producing effective medications but also in championing efforts to address the ongoing ADHD treatment supply shortage. Each year, their initiatives aim to raise the standard of care for individuals affected by ADHD.
Contact Information for Alora Pharmaceuticals
For more information about ADHD treatments and the company’s initiatives, individuals are encouraged to reach out to Alora Pharmaceuticals. Media inquiries can be directed to their office located at 1880 McFarland Parkway, Suite 110, Alpharetta, GA 30005, or by calling 1-678-325-5189.
Frequently Asked Questions
What is ADHD?
ADHD stands for Attention Deficit Hyperactivity Disorder, a neurodevelopmental disorder characterized by difficulties with attention, impulsivity, and hyperactivity.
What role does RELEXXII play in ADHD treatment?
RELEXXII is a medication used to manage ADHD symptoms, particularly suitable for individuals requiring long-acting treatment options.
How common is ADHD among children?
Approximately 10.2% of children aged 3 to 17 in the U.S. have been diagnosed with ADHD, illustrating its widespread impact.
Can adults have ADHD?
Yes, ADHD can persist into adulthood, with about 4-5% of adults in the U.S. being affected by the disorder.
What are common treatment methods for ADHD?
ADHD treatment typically includes a combination of medications, such as stimulants like RELEXXII, and behavioral therapy to enhance management strategies.
